Table 2.
Analysis | Group A | 95% CI | Group B | 95% CI | P |
---|---|---|---|---|---|
ITT | 88.6%(31/35) | 73.3%–96.8% | 85.7%(30/35) | 69.7%–95.2% | 1.000 |
PP | 96.9%(31/32) | 83.8%–99.9% | 96.8%(30/31) | 83.3%–99.9% | 1.000 |
Group A, H. pylori-infected patients treated with bismuth-containing quadruple therapy; Group B, H. pylori-infected patients treated with bismuth-containing quadruple therapy and supplemented with C. butyricum; ITT, intention to treat; PP, per protocol.